• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

核重编程与诱导多能干细胞:外科医生综述

Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.

作者信息

Qi Sara D, Smith Paul D, Choong Peter F

机构信息

Department of Surgery, St. Vincent's Hospital, University of Melbourne, Melbourne, Victoria, Australia.

出版信息

ANZ J Surg. 2014 Jun;84(6):417-23. doi: 10.1111/ans.12419.

DOI:10.1111/ans.12419
PMID:24894037
Abstract

Induced pluripotent stem cells (iPSCs) are generated from somatic cells by the exogenous expression of defined transcription factors. iPSCs share the defining features of embryonic stem cells (ESCs) in that they are able to self renew indefinitely and maintain the potential to develop into all cell types of the body. These cells have key advantages over ESCs in that they are autologous to the donor cells and can be generated from individuals at any age. iPSCs also circumvent ethical and political issues surrounding the destruction of embryos that is necessary in the isolation of ESCs. This review briefly describes the advent of iPSC technology and the concepts of nuclear reprogramming, and discusses the potential application of this powerful biological tool in both surgical research and regenerative medicine.

摘要

诱导多能干细胞(iPSC)是通过特定转录因子的外源表达从体细胞产生的。iPSC具有胚胎干细胞(ESC)的典型特征,即它们能够无限自我更新,并保持发育成身体所有细胞类型的潜力。这些细胞相对于ESC具有关键优势,因为它们与供体细胞同源,并且可以从任何年龄的个体中产生。iPSC还规避了围绕ESC分离过程中胚胎破坏的伦理和政治问题。本综述简要描述了iPSC技术的出现和核重编程的概念,并讨论了这种强大生物工具在外科研究和再生医学中的潜在应用。

相似文献

1
Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.核重编程与诱导多能干细胞:外科医生综述
ANZ J Surg. 2014 Jun;84(6):417-23. doi: 10.1111/ans.12419.
2
Nuclear reprogramming and induced pluripotent stem cells: a review for surgeons.核重编程与诱导多能干细胞:外科学者综述
ANZ J Surg. 2014 Jun;84(6):E1-11. doi: 10.1111/j.1445-2197.2012.06282.x. Epub 2012 Oct 4.
3
How far are induced pluripotent stem cells from the clinic?诱导多能干细胞离临床应用还有多远?
Ageing Res Rev. 2010 Jul;9(3):257-64. doi: 10.1016/j.arr.2010.03.001. Epub 2010 Apr 1.
4
Induced pluripotent stem cells: progress and future perspectives in the stem cell world.诱导多能干细胞:干细胞领域的进展与未来展望
Cell Reprogram. 2012 Dec;14(6):459-70. doi: 10.1089/cell.2012.0039. Epub 2012 Oct 4.
5
Will SCNT-ESCs be better than iPSCs for personalized regenerative medicine?对于个性化再生医学而言,体细胞核移植胚胎干细胞会比诱导多能干细胞更好吗?
Cell Stem Cell. 2013 Aug 1;13(2):141-2. doi: 10.1016/j.stem.2013.07.013.
6
Somatic cell reprogramming as a tool for neurodegenerative diseases.体细胞重编程作为神经退行性疾病的一种工具。
Biomed Pharmacother. 2019 Apr;112:108663. doi: 10.1016/j.biopha.2019.108663. Epub 2019 Mar 7.
7
Cell reprogramming: expectations and challenges for chemistry in stem cell biology and regenerative medicine.细胞重编程:化学在干细胞生物学和再生医学中的期望和挑战。
Cell Death Differ. 2010 Aug;17(8):1230-7. doi: 10.1038/cdd.2010.14. Epub 2010 Feb 19.
8
iPS cell technologies and cartilage regeneration.诱导多能干细胞技术与软骨再生。
Bone. 2015 Jan;70:48-54. doi: 10.1016/j.bone.2014.07.011. Epub 2014 Jul 12.
9
Evolution of induced pluripotent stem cell technology.诱导多能干细胞技术的演进。
Curr Opin Hematol. 2010 Jul;17(4):276-80. doi: 10.1097/MOH.0b013e328339f2ee.
10
Induced pluripotent stem (iPS) cells: a new source for cell-based therapeutics?诱导多能干细胞(iPS 细胞):细胞治疗的新来源?
J Control Release. 2014 Jul 10;185:37-44. doi: 10.1016/j.jconrel.2014.04.011. Epub 2014 Apr 16.

引用本文的文献

1
Human induced pluripotent stem cells ameliorate hyperoxia-induced lung injury in a mouse model.人诱导多能干细胞可改善小鼠模型中高氧诱导的肺损伤。
Am J Transl Res. 2020 Jan 15;12(1):292-307. eCollection 2020.
2
Factors and molecules that could impact cell differentiation in the embryo generated by nuclear transfer.可能影响核移植产生的胚胎中细胞分化的因素和分子。
Organogenesis. 2017 Oct 2;13(4):156-178. doi: 10.1080/15476278.2017.1389367.
3
Diabetes mellitus and cellular replacement therapy: Expected clinical potential and perspectives.
糖尿病与细胞替代疗法:预期的临床潜力与前景
World J Diabetes. 2014 Dec 15;5(6):777-86. doi: 10.4239/wjd.v5.i6.777.